ESMO Asia Congress 2024: Abstracts

The abstract submission system is now closed

View the abstracts in the online programme

Abstract submission deadlines

Outcome notifications

Outcome notifications are expected to be made available to first authors and submitters by mid-September 2024.

Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by mid-October 2024. 

Information for presenters

Detailed instructions for the preparation of slide presentations and/or posters will be made available on the ESMO website by mid-September 2024, in the section “Information for Presenters”.

Abstract submission categories

Late-breaking abstracts (LBA)

Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.

The final late-breaking abstract deadline of 8 October 2024 is under no circumstances to be considered as an extension of the general submission deadline (16 July 2024).

Trial in progress abstracts (TiP)

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Asia Congress 2024.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.

Young Oncologist (YO) Patient case studies

Challenging clinical case studies in the new era of personalised medicine may be submitted by young oncologists under 40 years of age.

Presentation and publication of accepted abstracts

The ESMO Asia 2024 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

• Presidential Symposium – Oral presentations by authors presenting cutting-edge and significant clinical practice-changing studies, followed by expert discussion and perspectives.
• Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
• Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
• Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.

All accepted abstracts, including late-breaking abstracts, will be published online only in the ESMO Asia Congress 2024 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.

Publication schedule of accepted abstracts

Details regarding the publication of accepted abstracts will be available here.

ESMO Merit Travel Grants 

A restricted number of Merit Travel Grants to the ESMO Asia Congress 2024 have been made available (upon application), and awarded to the following abstract presenters:

• Jian-Jian Chen, Nanjing, China
• Songji Choi, Seongnam, Republic of Korea
• Lin-Rui Gao, Beijing, China
• Animesh Gupta, Bangalore, India
• David Halafyan, Moscow, Russian Federation
• Shunichi Kataoka, Bunkyo-ku, Japan
• Avinash Khadela, Ahmedabad, India
• Mridul Khanna, Rishikesh, India
• Jee Hung Kim, Seoul, Republic of Korea
• Nesrine Kooli, Tunis, Tunisia
• Gianmarco Leone, London, United Kingdom
• Dong Luo, Changsha, China
• Brigida Maiorano, Rome, Italy
• Abdul Mannan, Dhaka, Bangladesh
• Yostena Mekhail, Shebeen El-Kom, Egypt
• Dang Nguyen, Ho Chi Minh City, Vietnam
• Hanh Nguyen, Ho Chi Minh City, Vietnam
• Chaitanya Patil, Kolkata, India
• Haoxin Peng, Beijing, China
• Lorenz Fort Revillas, Quezon City, Philippines
• Nam Tran, Ho Chi Minh City, Vietnam
• Sze Wa Tse, Kowloon, Hong Kong SAR, China
• Kompreeya Upalananda, Bangkok, Thailand
• Umesh Velu, Manipal, India
• Maria Carmela Vistal, Quezon City, Philippines
• Siti Mariam Yacob, Kubang Kerian, Malaysia
• Chih Chieh Yen, Tainan City, Taiwan
• Joseph J. Zhao, Singapore
• Jian-Hong Zhong, Nanning, China